



TECHNICAL DATA SHEET

002214-TDS-ENG-2025

CALCIO CITRATO TRIBASICO (USP / E 333)					
DESCRIPTION DCI: TRICALCIUM DICITRATE		DESCRIPTION DOE: TRICALCIO DICITRATO			
CAS Nº: 5785-44-4	EC Nº: 212-391-7		AEMPS CODE:		
MOL. WEIGHT: 570,51	MOL. FORMULA: C12Ca3H10O14*4H2O		ARTICLE CODE: 002214		

ATTRIBUTES	SHOULD BE		
Identification A	Complies		
Identification B	Complies		
Assay	97.5 - 100.5 %		
Arsenic	=< 3 ppm		
Lead	=< 10 ppm		
Limit of fluoride	=< 0.003 %		
Limit of acid-insoluble substances	=< 0.2 %		
Loss on drying	10.0 - 13.3 %		

COMPLIES WITH

USP 2025

STORAGE

Keep the containers tightly closed. Store it in a well-ventilated and dry place.

REMARKS

Product suitable as an alimentary excipient.

Applications

It is an agent used as a dietary supplement of calcium, the main component of bones and which plays an important biological role in muscle activity and neuromuscular transmission, absorbing 20 - 35% of the oral dose in the small intestine through a Active transport mechanism dependent on vitamin D. It is used, orally, in the treatment of hypocalcemia and in the therapy of calcium deficiency states, acting as a coadjuvant in the prophylaxis and treatment of osteoporosis.

Dose

The dosages for adults are up to 50 mmol of calcium per day, divided into 2 - 4 doses, advising the joint use of Vitamin D.

Side effects

Its oral administration can produce gastrointestinal irritation and constipation. At excessively high doses causes hypercalcemia, especially in patients with renal failure. Symptoms of hyperkalaemia include anorexia, nausea, vomiting, constipation, abdominal pain, muscle cramps, polydipsia, polyuria, bone pain, nephrocalcinosis, kidney stones and, in severe cases, cardiac arrhythmias and coma.

Precautions

It is contraindicated in hypercalcemia, hypercalciuria and ventricular fibrillation. A special medical check should be carried out on individuals with renal insufficiency, heart disease, hypoparathyroidism and sarcoidosis. It can aggravate the disease in patients with renal calcium stones. Calcemia should be monitored periodically in individuals who take concomitant high dosages of vitamin D in prolonged therapy with calcium supplements or severe renal insufficiency.

Interactions

It can reduce the oral absorption of iron salts, tetracyclines and phenytoin. It can enhance the toxicity of digitalis glycosides. Thiazide diuretics may increase renal calcium reabsorption, leading to hypercalcemia.

Compounding examples

CALCIUM CITRATE - 1 g

All methods are validated by the official pharmacopoeias and/or by the authorized manufacturer





TECHNICAL DATA SHEET

002214-TDS-ENG-2025

CALCIO CITRATO TRIBASICO (USP / E 333)					
DESCRIPTION DCI: TRICALCIUM DICITRATE		DESCRIPTION DOE: TRICALCIO DICITRATO			
CAS Nº: 5785-44-4	EC Nº: 212-391-7		AEMPS CODE:		
MOL. WEIGHT: 570,51	MOL. FORMULA: C12Ca3H10O14*4H2O		ARTICLE CODE: 002214		

for capsules nº 100